Prab: CSV import

2025-02-13T03:41:24Z

CSV import

← Older revision		Revision as of 03:41, 13 February 2025
Line 1:		Line 1:
	~~'''~~Nepadutant''' is a drug that acts as a selective antagonist for the [[neurokinin 1 receptor]]. It was developed by [[Menarini]] and is used in the treatment of [[irritable bowel syndrome]] (IBS) and other [[gastrointestinal disorders]].		{{DISPLAYTITLE:Nepadutant}}

	== ~~Pharmacology~~ ==		== Overview ==
			'''Nepadutant''' is a [[pharmacological]] compound that acts as a selective antagonist of the [[neurokinin-2 receptor]] (NK2 receptor). It is primarily used in research settings to study the physiological and pathological roles of [[neurokinin]]s, particularly in the context of [[gastrointestinal]] and [[respiratory]] systems.

	Nepadutant ~~selectively blocks~~ the ~~neurokinin 1 (NK1) receptor. The~~ [[neurokinin ~~1 receptor~~]] is a ~~G protein-coupled~~ receptor ~~located in the central and peripheral nervous system~~. ~~It is involved in~~ various ~~physiological processes~~, including ~~pain perception and~~ smooth muscle contraction in ~~the gastrointestinal tract. By blocking this receptor~~, ~~nepadutant can reduce the symptoms of IBS~~ and other ~~gastrointestinal disorders~~.		== Mechanism of Action ==
			Nepadutant functions by inhibiting the action of [[neurokinin A]], a [[neuropeptide]] that binds to the NK2 receptor. By blocking this receptor, nepadutant can modulate various biological responses, including smooth muscle contraction and [[inflammation]]. This makes it a valuable tool in understanding diseases such as [[asthma]], [[irritable bowel syndrome]], and other conditions where neurokinin A is implicated.

	== ~~Clinical trials~~ ==		== Pharmacokinetics ==
			The pharmacokinetic profile of nepadutant includes its absorption, distribution, metabolism, and excretion characteristics. It is typically administered in experimental settings via [[intravenous]] or [[oral]] routes. The compound is known for its high specificity and affinity for the NK2 receptor, which contributes to its effectiveness in blocking neurokinin A-mediated responses.

	~~Nepadutant~~ has ~~undergone Phase II clinical trials for the treatment of irritable bowel syndrome~~. ~~The results of these trials~~ have ~~shown that nepadutant can significantly~~ reduce ~~the symptoms of IBS~~, ~~including abdominal pain~~ and ~~discomfort~~, ~~bloating, and altered bowel habits~~.		== Clinical Applications ==
			While nepadutant is not currently approved for clinical use, its role in research has provided insights into potential therapeutic applications. Studies have explored its use in managing conditions like [[asthma]], where it may help reduce bronchoconstriction, and in [[gastrointestinal disorders]], where it could alleviate symptoms by reducing smooth muscle contractions.

	== ~~Side effects~~ ==		== Research and Development ==
			Research on nepadutant continues to explore its potential benefits and applications. Ongoing studies aim to better understand its effects on various [[pathophysiological]] processes and to develop derivatives with improved efficacy and safety profiles.

	~~The most common side effects of nepadutant include headache, dizziness, and gastrointestinal symptoms such as nausea and diarrhea. These side effects are generally mild and transient.~~		== Related Pages ==
			* [[Neurokinin receptor]]
	== ~~See also~~ ==		* [[Neurokinin A]]
			* [[Asthma]]
	* [[Neurokinin ~~1 receptor~~]]
	* [[Irritable bowel syndrome]]		* [[Irritable bowel syndrome]]
	* [[Gastrointestinal disorders]]
	* [[Menarini]]

	~~[[Category:Drugs]]~~		== Gallery ==
	~~[[Category:Gastrointestinal drugs]]~~		[[File:Nepadutant.svg\|thumb\|right\|Chemical structure of nepadutant]]
	[[~~Category~~:~~Neurokinin 1 receptor antagonists~~]]

	~~{{stub}}~~		[[Category:Pharmacology]]
			[[Category:Neurokinin receptor antagonists]]

Prab: CSV import

2024-02-25T21:13:24Z

CSV import

New page

'''Nepadutant''' is a drug that acts as a selective antagonist for the [[neurokinin 1 receptor]]. It was developed by [[Menarini]] and is used in the treatment of [[irritable bowel syndrome]] (IBS) and other [[gastrointestinal disorders]].

== Pharmacology ==

Nepadutant selectively blocks the neurokinin 1 (NK1) receptor. The [[neurokinin 1 receptor]] is a G protein-coupled receptor located in the central and peripheral nervous system. It is involved in various physiological processes, including pain perception and smooth muscle contraction in the gastrointestinal tract. By blocking this receptor, nepadutant can reduce the symptoms of IBS and other gastrointestinal disorders.

== Clinical trials ==

Nepadutant has undergone Phase II clinical trials for the treatment of irritable bowel syndrome. The results of these trials have shown that nepadutant can significantly reduce the symptoms of IBS, including abdominal pain and discomfort, bloating, and altered bowel habits.

== Side effects ==

The most common side effects of nepadutant include headache, dizziness, and gastrointestinal symptoms such as nausea and diarrhea. These side effects are generally mild and transient.

== See also ==

* [[Neurokinin 1 receptor]]
* [[Irritable bowel syndrome]]
* [[Gastrointestinal disorders]]
* [[Menarini]]

[[Category:Drugs]]
[[Category:Gastrointestinal drugs]]
[[Category:Neurokinin 1 receptor antagonists]]

{{stub}}

Nepadutant - Revision history

Prab: CSV import

Prab: CSV import